



## Transparency notification

Brussels (Belgium), 30 December 2016 – 20:00 (CET) – regulated information

### 1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 27 December 2016, from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02110, USA).

Wellington Management Group LLP has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV had decreased and has crossed downward the 3% threshold.

On 23 December 2016, Wellington Management Group LLP (taking into account the holding of its affiliates) owned 5 814 498 UCB shares with voting rights (versus 5 836 623 UCB shares in its previous notification dated 22 December 2016), representing 2.99% of the total number of shares issued by the company (194 505 658) (versus 3.00% in its notification dated 22 December 2016).

### 2. Content of the notification

The transparency notification dated 27 December 2016 included the following information:

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights
- **Notification by:** A parent undertaking or a controlling person.
- **Person subject to the notification requirement:** Wellington Management Group LLP, 280 Congress Street, Boston, MA 02110, USA
- **Date on which the threshold is crossed:** 23 December 2016.
- **Threshold crossed (in %):** 3%.
- **Denominator:** 194 505 658.

- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holder of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Wellington Management Group LLP	0	0		0,00%	
Wellington Management Company LLP	4.669.944	4.661.557		2,40%	
Wellington Management International Ltd	1.166.679	1.152.941		0,59%	
Subtotal	5.836.623	5.814.498		2,99%	
<b>TOTAL</b>		<b>5.814.498</b>		<b>2,99%</b>	

  

TOTAL (A & B)		# of voting rights	% of voting rights
		<b>CALCULATE</b>	
		5.814.498	2,99%

- **Chain of controlled undertakings through which the holding is effectively held:**

Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.

Wellington Management International Ltd, is a direct controlled undertaking of Wellington Management Global Holdings, Ltd, which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.

- **Additional information:**

Wellington Management Company LLP is an investment management company and can exercise the voting rights at its discretion in the absence of specific instructions from the beneficial owners of the shares.

Wellington Management International Ltd is an investment management company and can exercise the voting rights at its discretion in the absence of specific instructions from the beneficial owners of the shares.

### 3. Further information

This press release and the detailed transparency notification is available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website via the following [link](#).

## Investor Relations

Antje Witte,  
Investor Relations, UCB  
T +32 2 559 94 14,  
antje.witte@ucb.com

Isabelle Ghellynck,  
Investor Relations, UCB  
T +32 2 559 95 88,  
isabelle.ghellynck@ucb.com

## About UCB

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of €3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news